Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
CN Stock MarketDetailed Quotes
688617 APT Medical Inc.
- 439.02
- +8.46+1.96%
Market Closed Apr 24 15:00 CST
42.62BMarket Cap59.51P/E (TTM)
443.60High428.25Low5.78KlotVolume432.00Open430.56Pre Close253.17MTurnover0.60%Turnover Ratio63.31P/E (Static)97.08MShares480.0052wk High15.78P/B42.62BFloat Cap292.5452wk Low516.67Limit Up97.08MShs Float480.00Historical High344.45Limit Down3.57%Amplitude94.85Historical Low1.38Dividend TTM437.70Avg Price2.85KlotAsk0.31%Div YieldTTM100Lot Size2.42KlotBid
APT Medical Inc. News
APT Medical's 2024 Profit Rises 26%, Operating Income Climbs 25%; Shares Drop 4%
Huitai Healthcare: 2024 Annual Report Summary
Huitai Healthcare: First Quarter Report 2025
Huitai Healthcare: 2024 Annual Report
2024 ANNUAL REPORT
2024 Annual Report Summary
2025 First Quarter Report
Gelonghui Announcement Selected: Sunyard Technology: The cross-border payment business involved by the company is not its main product; APT Medical Inc.: In 2024, the Net income is projected to grow by 26.08% year-on-year, planning a 10 to 4.5 bonus with
【Hotspot Tracking】Gansu Guofang Industry & Trade (601086.SH): The company's stock has seen a short-term increase significantly higher than the Industry Index, with substantial irrational speculation and very high trading risks. Sunyard Technology (600571.SH): The cross-border payment business involved is not the company's main product. Anhui Anli Material Technology (300218.SZ): The overall tariff risk is controllable. 【Project Investment】3onedata Co., Ltd. (688618.SH): Plans to jointly invest with Jiuzhao Investment in the Wuhe Jiuzhao 3onedata Fund. Bi Yi Co., Ltd. (603215.SH): Plans to jointly invest with the controlling Shareholder to establish a private equity fund. Hui Green Ecology (001267.
Express News | Apt Medical Says 2024 Net Profit up 26.1% Y/Y
Express News | Apt Medical Q1 Net Profit up 30.7% Y/Y
APT Medical Inc. (688617.SH): In 2024, net income is expected to grow by 26.08% year-on-year, with a proposal for a 10-for-4.5 stock split and a dividend of 17.50 yuan.
On April 22, Gelonghui reported that APT Medical Inc. (688617.SH) announced its 2024 annual report, achieving revenue of 2.066 billion yuan during the reporting period, a year-on-year increase of 25.18%; net income attributable to shareholders of the listed company was 0.673 billion yuan, up 26.08% year-on-year; basic EPS was 6.96 yuan. A cash dividend of 17.50 yuan (including tax) is proposed to be distributed to all shareholders for every 10 shares, and the company plans to convert 4.5 shares for every 10 shares from capital reserves, without issuing bonus shares.
Shareholders Would Enjoy A Repeat Of APT Medical's (SHSE:688617) Recent Growth In Returns
APT Medical Inc. (688617.SH): Vice General Manager Han Yonggui plans to reduce his shareholding by no more than 0.03 million shares.
On April 3, Glorious Securities reported that APT Medical Inc. (688617.SH) announced that it had recently received a notice from Mr. Han Yonggui, the company's deputy general manager, regarding the shareholding reduction plan. The reduction entity plans to reduce its holdings by no more than 30,000 shares, which is no more than 0.0309% of the company's total share capital. For reductions made through centralized bidding, the total number of shares reduced within any 90 consecutive calendar days will not exceed 1% of the company's total share capital, with the reduction period set for three months starting from the 15th trading day after the announcement date; for reductions made through block trading, in任
APT Medical Inc. (688617.SH): DeepSeek has not yet been deployed.
On March 26, Glenwood reported that APT Medical Inc. (688617.SH) stated on the interactive platform that as of now, the company has not deployed DeepSeek. The company will continue to pay attention to the development of AI technology and explore its application in Business.
Risks To Shareholder Returns Are Elevated At These Prices For APT Medical Inc. (SHSE:688617)
APT Medical Gets Registration Certificate for Vena Cava Filter System
APT Medical Gets Medical Device Registration for Medical Catheter Sensor
APT Medical Inc. (688617.SH): The disposable magnetic positioning pressure monitoring radiofrequency ablation catheter has obtained the medical instruments registration certificate.
On February 26, Glonghui reported that APT Medical Inc. (688617.SH) announced that its wholly-owned subsidiary Hunan APT Medical Instruments Co., Ltd. has obtained a medical instruments registration certificate for the product name: disposable magnetic positioning pressure monitoring radiofrequency ablation catheter. The acquisition of this medical instruments registration certificate is beneficial for enriching the company's product variety, expanding the company's product layout in the field of electrophysiology, continuously meeting diverse clinical needs, and further enhancing the company's core competitiveness.
Research Reports Mining丨Founder Securities: APT Medical Inc.'s overall performance in Q4 remains stable, maintaining a 'recommended' rating.
The research report from Founder Securities indicates that APT Medical Inc. (688617.SH) has stable overall growth in its main business, with domestic growth currently under pressure. The launch of the PFA is expected to drive performance back to high growth. In the fourth quarter, the company achieved over 20% year-on-year growth in both revenue and net income excluding non-recurring items, maintaining consistent performance. On December 16, 2024, the disposable cardiac pulsed electric field ablation catheter (PFA) was approved by the NMPA, and this technology is rapidly penetrating the atrial fibrillation market. It is expected to drive surgical upgrades through better clinical outcomes, contributing new acceleration to the company's performance. In 2024, the company will continue to operate in the overseas market with its own brand.
Huitai Healthcare: 2024 Annual Results Express Announcement
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs